{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:11:21Z","timestamp":1793272281632,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.coi.2026.102743","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:03:52Z","timestamp":1772575432000},"page":"102743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Clinical trials and new therapies in Sj\u00f6gren\u2019s disease"],"prefix":"10.1016","volume":"100","author":[{"given":"Vishal","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Grader-Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102743_sbref1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41584-023-01057-6","article-title":"Epidemiology of Sjogren syndrome","volume":"20","author":"Beydon","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib2","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/annrheumdis-2016-209952","article-title":"Influence of geolocation and ethnicity on the phenotypic expression of primary Sj\u00f6gren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sj\u00f6gren Project Consortium","volume":"76","author":"Brito-Zer\u00f3n","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102743_bib3","article-title":"Primary Sjogren's syndrome","volume":"379","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102743_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/clin.1994.1123","article-title":"Sjogren's syndrome: autoimmune epithelitis","volume":"72","author":"Moutsopoulos","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.coi.2026.102743_bib5","first-page":"271","article-title":"When B cells break bad: development of pathogenic B cells in Sjogren's syndrome","volume":"38","author":"Reed","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib6","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/art.39214","article-title":"Prediction of Sjogren's syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling","volume":"67","author":"Theander","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard.2006.052647","article-title":"Progression of salivary gland dysfunction in patients with Sjogren's syndrome","volume":"66","author":"Pijpe","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102743_bib8","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/rheumatology\/kez578","article-title":"Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjogren's syndrome","volume":"59","author":"Brito-Zeron","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102743_sbref9","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3899\/jrheum.2024-1012","article-title":"A systematic review of clinical trial designs and outcome measures in Sjogren disease randomized controlled trials","volume":"52","author":"Beydon","year":"2025","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib10","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren's syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib11","first-page":"2249","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sj\u00f6gren's syndrome: the BELISS open-label phase II study","volume":"54","author":"De Vita","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102743_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2026.102743_sbref13","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","article-title":"Efficacy and safety of telitacicept in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"63","author":"Xu","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102743_sbref14","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(24)01211-X","article-title":"Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjogren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study","volume":"404","author":"Fisher","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2026.102743_sbref15","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","article-title":"CD40 ligand antagonist dazodalibep in Sj\u00f6gren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial","volume":"30","author":"St Clair","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2026.102743_bib16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sj\u00f6gren's syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102743_bib17","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.40513","article-title":"Clinical efficacy and safety of baminercept, a lymphotoxin \u03b2 receptor fusion protein, in primary Sj\u00f6gren\u2019s syndrome: results from a phase II randomized, double-blind, placebo-controlled trial","volume":"70","author":"St Clair","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2020-218467","article-title":"Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial","volume":"80","author":"Felten","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102743_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren\u2019s syndrome\u2014a double blind, randomised clinical trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2026.102743_bib20","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sj\u00f6gren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102743_bib21","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sj\u00f6gren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj\u00f6gren's Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102743_bib22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/art.41489","article-title":"Improvement of severe fatigue following nuclease therapy in patients with primary Sj\u00f6gren's syndrome: a randomized clinical trial","volume":"73","author":"Posada","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib23","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/art.11199","article-title":"Treatment of primary Sj\u00f6gren\u2019s syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III\u00a0results","volume":"49","author":"Cummins","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102743_bib24","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1089\/107999099313497","article-title":"Treatment of primary Sjogren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group","volume":"19","author":"Ship","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.coi.2026.102743_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.41451","article-title":"Efficacy and safety of low-dose interleukin 2 for primary Sj\u00f6gren syndrome: a randomized clinical trial","volume":"5","author":"He","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.coi.2026.102743_bib26","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard-2023-224691","article-title":"Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjogren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial","volume":"83","author":"Dorner","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102743_bib27","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","article-title":"Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sj\u00f6gren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study","volume":"61","author":"Price","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102743_bib28","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/rheumatology\/keaa410","article-title":"A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sj\u00f6gren\u2019s syndrome","volume":"60","author":"Juarez","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.coi.2026.102743_bib29","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1007\/s10792-020-01490-6","article-title":"The efficacy and mechanism for action of iguratimod in primary Sj\u00f6gren\u2019s syndrome patients","volume":"40","author":"Jiang","year":"2020","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.coi.2026.102743_bib30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/03009742.2020.1809701","article-title":"Efficacy and safety of iguratimod on patients with primary Sj\u00f6gren\u2019s syndrome: a randomized, placebo-controlled clinical trial","volume":"50","author":"Shao","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib31","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102743_bib32","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1093\/rheumatology\/kev200","article-title":"Characterization of systemic disease in primary Sjogren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements","volume":"54","author":"Ramos-Casals","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102743_bib33","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1136\/annrheumdis-2015-208504","article-title":"Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies","volume":"75","author":"Seror","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102743_bib34","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102743_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152378","article-title":"The Sj\u00f6gren's Working Group: The 2023 OMERACT meeting and provisional domain generation","volume":"65","author":"Gordon","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102743_sbref36","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","article-title":"Development and preliminary validation of the Sj\u00f6gren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren's syndrome","volume":"81","author":"Seror","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102743_sbref37","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of Relevant Endpoints for Sj\u00f6gren's Syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib38","unstructured":"Seror R., Baron G., Perrodeau E., Piatrova A., Bootsma H., Bowman S., Gottenberg J., Cornec D., Bombardieri M., Arends S., et al.: The Sj\u00f6gren\u2019s Tool for Assessing Response (STAR) demonstrates its ability to accurately detect treatment efficacy in 11 recent RCTs in Sj\u00f6gren\u2019s disease. In ACR Convergence 2025; 2025. Edited by. Chicago, IL, USA."},{"key":"10.1016\/j.coi.2026.102743_bib39","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/S2665-9913(19)30042-6","article-title":"Symptom-based stratification of patients with primary Sj\u00f6gren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials","volume":"1","author":"Tarn","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib40","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00296-021-04927-y","article-title":"Revisiting the JOQUER trial: stratification of primary Sj\u00f6gren's syndrome and the clinical and interferon response to hydroxychloroquine","volume":"41","author":"Collins","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.coi.2026.102743_sbref40","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2665-9913(23)00340-5","article-title":"Identification of distinct subgroups of Sj\u00f6gren\u2019s disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts","volume":"6","author":"Nguyen","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib42","unstructured":"Grader-Beck T., Mariette X., Finzel S., Schiopu E., Papas A., Dvauchelle-Pensec V., D\u00f6rner T., Sopala M., Zeng X., Noaiseh G., et al.: LB 24 ianalumab demonstrates significant reduction in disease activity in patients with Sj\u00f6gren\u2019s disease: efficacy and safety results from two global phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2). In ACR Convergence 2025. Edited by. Chicago, IL; 2025."},{"key":"10.1016\/j.coi.2026.102743_bib43","unstructured":"D X., S Z., L Q., L Z., W W., L L., B X., J Z., Q Z., J F., et al.: LB11 efficacy and safety of telitacicept in patients with Sj\u00f6gren\u2019s disease: results from a multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical study. In ACR Convergence 2025; 2025. Edited by. Chicago, IL."},{"key":"10.1016\/j.coi.2026.102743_bib44","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren's syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.coi.2026.102743_sbref42","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/S0140-6736(25)01430-8","article-title":"Efficacy and safety of nipocalimab in patients with moderate-to-severe Sj\u00f6gren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial","volume":"406","author":"Noaiseh","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2026.102743_bib46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ard.2025.05.065","article-title":"Treatment of primary Sj\u00f6gren's disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod","volume":"84","author":"Peene","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102743_bib47","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","article-title":"Leflunomide\u2013hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren\u2019s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial","volume":"2","author":"Van der Heijden","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib48","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome: the JOQUER randomized clinical trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.coi.2026.102743_bib49","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib50","article-title":"Systematic review with meta-analysis: efficacy and safety of biological treatment on salivary gland function in primary Sjogren's syndrome","volume":"14","author":"Wang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coi.2026.102743_bib51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/ard.2007.071563","article-title":"Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sj\u00f6gren syndrome: a randomised controlled trial","volume":"67","author":"Hartkamp","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102743_bib52","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/acr.20022","article-title":"Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA-deficient patients with primary Sj\u00f6gren\u2019s syndrome","volume":"62","author":"Virkki","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.coi.2026.102743_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren's syndrome--a double blind, randomised clinical trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2026.102743_bib54","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.coi.2026.102743_bib55","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102743_bib56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coi.2026.102743_bib57","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/art.39088","article-title":"Brief report: ultrasonographic assessment of salivary gland response to rituximab in primary Sj\u00f6gren's syndrome","volume":"67","author":"Jousse-Joulin","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib58","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/annrheumdis-2017-212268","article-title":"Effect of rituximab on a salivary gland ultrasound score in primary Sj\u00f6gren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy","volume":"77","author":"Fisher","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102743_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162787","article-title":"High-grade salivary-gland involvement, assessed by histology or ultrasonography, is associated with a poor response to a single rituximab course in primary Sjogren's syndrome: data from the TEARS randomized trial","volume":"11","author":"Cornec","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2026.102743_bib60","doi-asserted-by":"crossref","DOI":"10.1186\/ar4359","article-title":"Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multi-center, follow-up study","volume":"15","author":"Carubbi","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coi.2026.102743_bib61","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/art.24903","article-title":"Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjogren's syndrome","volume":"60","author":"Pijpe","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102743_bib62","first-page":"228","article-title":"Ianalumab (VAY736) in primary Sjogren's syndrome: assessing disease activity using multi-modal ultrasound","volume":"38","author":"Diekhoff","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib63","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjogren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib64","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1136\/annrheumdis-2015-208304","article-title":"Towards personalised treatment in primary Sjogren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment","volume":"75","author":"Delli","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102743_bib65","first-page":"317","article-title":"Abatacept treatment of patients with primary Sjogren's syndrome results in a decrease of germinal centres in salivary gland tissue","volume":"35","author":"Haacke","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib66","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/art.42772","volume":"76","author":"Pontarini","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib67","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren's syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102743_bib68","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sj\u00f6gren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102743_bib69","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102743_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1298815","article-title":"Concurrent remission of lymphoma and Sj\u00f6gren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report","volume":"14","author":"Sheng","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102743_bib71","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.neurom.2022.08.461","article-title":"The effects of noninvasive vagus nerve stimulation on fatigue in participants with primary Sjogren's syndrome","volume":"26","author":"Tarn","year":"2023","journal-title":"Neuromodulation"},{"key":"10.1016\/j.coi.2026.102743_bib72","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/ner.12879","article-title":"The effects of noninvasive vagus nerve stimulation on fatigue and immune responses in patients with primary Sjogren's syndrome","volume":"22","author":"Tarn","year":"2019","journal-title":"Neuromodulation"},{"key":"10.1016\/j.coi.2026.102743_bib73","article-title":"Effect of adipose tissue-derived stem cells therapy on clinical response in patients with primary Sjogren's syndrome","volume":"13","author":"Li","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2026.102743_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jtos.2023.11.007","article-title":"Allogeneic mesenchymal stem cell therapy for dry eye disease in patients with Sjogren's syndrome: a randomized clinical trial","volume":"31","author":"Moller-Hansen","year":"2024","journal-title":"Ocul Surf"},{"key":"10.1016\/j.coi.2026.102743_bib75","doi-asserted-by":"crossref","first-page":"19403","DOI":"10.1073\/pnas.1210662109","article-title":"Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction","volume":"109","author":"Baum","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coi.2026.102743_bib76","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/gt.2016.87","article-title":"Late responses to adenoviral-mediated transfer of the aquaporin-1 gene for radiation-induced salivary hypofunction","volume":"24","author":"Alevizos","year":"2017","journal-title":"Gene Ther"},{"key":"10.1016\/j.coi.2026.102743_sbref74","article-title":"GZMK(+)CD8(+) T cells target a specific acinar cell type in Sjogren's disease","author":"Pranzatelli","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102743_sbref75","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3899\/jrheum.210633","article-title":"PROMIS provides a broader overview of health-related quality of life than the ESSPRI in evaluation of Sjogren syndrome","volume":"49","author":"DiRenzo","year":"2022","journal-title":"J Rheumatol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:21:26Z","timestamp":1779510086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791526000208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":78,"alternative-id":["S0952791526000208"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102743","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trials and new therapies in Sj\u00f6gren\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102743"}}